Virus-specific T cells engineered to coexpress tumor-specific receptors

Persistence and antitumor activity in individuals with neuroblastoma

Martin A. Pule, Barbara Savoldo, G. Doug Myers, Claudia Rossig, Heidi V. Russell, Gianpietro Dotti, M. Helen Huls, Enli Liu, Adrian P. Gee, Zhuyong Mei, Eric Yvon, Heidi L. Weiss, Hao Liu, Cliona M. Rooney, Helen E. Heslop, Malcolm K. Brenner

Research output: Contribution to journalArticle

682 Citations (Scopus)

Abstract

Cytotoxic T lymphocytes (CTLs) directed to nonviral tumor-associated antigens do not survive long term and have limited antitumor activity in vivo, in part because such tumor cells typically lack the appropriate costimulatory molecules. We therefore engineered Epstein-Barr virus (EBV)-specific CTLs to express a chimeric antigen receptor directed to the diasialoganglioside GD2, a nonviral tumor-associated antigen expressed by human neuroblastoma cells. We reasoned that these genetically engineered lymphocytes would receive optimal costimulation after engagement of their native receptors, enhancing survival and antitumor activity mediated through their chimeric receptors. Here we show in individuals with neuroblastoma that EBV-specific CTLs expressing a chimeric GD2-specific receptor indeed survive longer than T cells activated by the CD3-specific antibody OKT3 and expressing the same chimeric receptor but lacking virus specificity. Infusion of these genetically modified cells seemed safe and was associated with tumor regression or necrosis in half of the subjects tested. Hence, virus-specific CTLs can be modified to function as tumor-directed effector cells.

Original languageEnglish (US)
Pages (from-to)1264-1270
Number of pages7
JournalNature Medicine
Volume14
Issue number11
DOIs
StatePublished - Nov 1 2008
Externally publishedYes

Fingerprint

T-cells
Cytotoxic T-Lymphocytes
Neuroblastoma
Viruses
Tumors
T-Lymphocytes
Neoplasm Antigens
Human Herpesvirus 4
Neoplasms
Virus Receptors
Muromonab-CD3
Antigen Receptors
Antigens
Lymphocytes
Necrosis
Cells
Survival
Antibodies
Molecules

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Pule, M. A., Savoldo, B., Myers, G. D., Rossig, C., Russell, H. V., Dotti, G., ... Brenner, M. K. (2008). Virus-specific T cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma. Nature Medicine, 14(11), 1264-1270. https://doi.org/10.1038/nm.1882

Virus-specific T cells engineered to coexpress tumor-specific receptors : Persistence and antitumor activity in individuals with neuroblastoma. / Pule, Martin A.; Savoldo, Barbara; Myers, G. Doug; Rossig, Claudia; Russell, Heidi V.; Dotti, Gianpietro; Huls, M. Helen; Liu, Enli; Gee, Adrian P.; Mei, Zhuyong; Yvon, Eric; Weiss, Heidi L.; Liu, Hao; Rooney, Cliona M.; Heslop, Helen E.; Brenner, Malcolm K.

In: Nature Medicine, Vol. 14, No. 11, 01.11.2008, p. 1264-1270.

Research output: Contribution to journalArticle

Pule, MA, Savoldo, B, Myers, GD, Rossig, C, Russell, HV, Dotti, G, Huls, MH, Liu, E, Gee, AP, Mei, Z, Yvon, E, Weiss, HL, Liu, H, Rooney, CM, Heslop, HE & Brenner, MK 2008, 'Virus-specific T cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma', Nature Medicine, vol. 14, no. 11, pp. 1264-1270. https://doi.org/10.1038/nm.1882
Pule, Martin A. ; Savoldo, Barbara ; Myers, G. Doug ; Rossig, Claudia ; Russell, Heidi V. ; Dotti, Gianpietro ; Huls, M. Helen ; Liu, Enli ; Gee, Adrian P. ; Mei, Zhuyong ; Yvon, Eric ; Weiss, Heidi L. ; Liu, Hao ; Rooney, Cliona M. ; Heslop, Helen E. ; Brenner, Malcolm K. / Virus-specific T cells engineered to coexpress tumor-specific receptors : Persistence and antitumor activity in individuals with neuroblastoma. In: Nature Medicine. 2008 ; Vol. 14, No. 11. pp. 1264-1270.
@article{cf8cf6c63f7c43e3ac10d0298ce07f7a,
title = "Virus-specific T cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma",
abstract = "Cytotoxic T lymphocytes (CTLs) directed to nonviral tumor-associated antigens do not survive long term and have limited antitumor activity in vivo, in part because such tumor cells typically lack the appropriate costimulatory molecules. We therefore engineered Epstein-Barr virus (EBV)-specific CTLs to express a chimeric antigen receptor directed to the diasialoganglioside GD2, a nonviral tumor-associated antigen expressed by human neuroblastoma cells. We reasoned that these genetically engineered lymphocytes would receive optimal costimulation after engagement of their native receptors, enhancing survival and antitumor activity mediated through their chimeric receptors. Here we show in individuals with neuroblastoma that EBV-specific CTLs expressing a chimeric GD2-specific receptor indeed survive longer than T cells activated by the CD3-specific antibody OKT3 and expressing the same chimeric receptor but lacking virus specificity. Infusion of these genetically modified cells seemed safe and was associated with tumor regression or necrosis in half of the subjects tested. Hence, virus-specific CTLs can be modified to function as tumor-directed effector cells.",
author = "Pule, {Martin A.} and Barbara Savoldo and Myers, {G. Doug} and Claudia Rossig and Russell, {Heidi V.} and Gianpietro Dotti and Huls, {M. Helen} and Enli Liu and Gee, {Adrian P.} and Zhuyong Mei and Eric Yvon and Weiss, {Heidi L.} and Hao Liu and Rooney, {Cliona M.} and Heslop, {Helen E.} and Brenner, {Malcolm K.}",
year = "2008",
month = "11",
day = "1",
doi = "10.1038/nm.1882",
language = "English (US)",
volume = "14",
pages = "1264--1270",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Virus-specific T cells engineered to coexpress tumor-specific receptors

T2 - Persistence and antitumor activity in individuals with neuroblastoma

AU - Pule, Martin A.

AU - Savoldo, Barbara

AU - Myers, G. Doug

AU - Rossig, Claudia

AU - Russell, Heidi V.

AU - Dotti, Gianpietro

AU - Huls, M. Helen

AU - Liu, Enli

AU - Gee, Adrian P.

AU - Mei, Zhuyong

AU - Yvon, Eric

AU - Weiss, Heidi L.

AU - Liu, Hao

AU - Rooney, Cliona M.

AU - Heslop, Helen E.

AU - Brenner, Malcolm K.

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Cytotoxic T lymphocytes (CTLs) directed to nonviral tumor-associated antigens do not survive long term and have limited antitumor activity in vivo, in part because such tumor cells typically lack the appropriate costimulatory molecules. We therefore engineered Epstein-Barr virus (EBV)-specific CTLs to express a chimeric antigen receptor directed to the diasialoganglioside GD2, a nonviral tumor-associated antigen expressed by human neuroblastoma cells. We reasoned that these genetically engineered lymphocytes would receive optimal costimulation after engagement of their native receptors, enhancing survival and antitumor activity mediated through their chimeric receptors. Here we show in individuals with neuroblastoma that EBV-specific CTLs expressing a chimeric GD2-specific receptor indeed survive longer than T cells activated by the CD3-specific antibody OKT3 and expressing the same chimeric receptor but lacking virus specificity. Infusion of these genetically modified cells seemed safe and was associated with tumor regression or necrosis in half of the subjects tested. Hence, virus-specific CTLs can be modified to function as tumor-directed effector cells.

AB - Cytotoxic T lymphocytes (CTLs) directed to nonviral tumor-associated antigens do not survive long term and have limited antitumor activity in vivo, in part because such tumor cells typically lack the appropriate costimulatory molecules. We therefore engineered Epstein-Barr virus (EBV)-specific CTLs to express a chimeric antigen receptor directed to the diasialoganglioside GD2, a nonviral tumor-associated antigen expressed by human neuroblastoma cells. We reasoned that these genetically engineered lymphocytes would receive optimal costimulation after engagement of their native receptors, enhancing survival and antitumor activity mediated through their chimeric receptors. Here we show in individuals with neuroblastoma that EBV-specific CTLs expressing a chimeric GD2-specific receptor indeed survive longer than T cells activated by the CD3-specific antibody OKT3 and expressing the same chimeric receptor but lacking virus specificity. Infusion of these genetically modified cells seemed safe and was associated with tumor regression or necrosis in half of the subjects tested. Hence, virus-specific CTLs can be modified to function as tumor-directed effector cells.

UR - http://www.scopus.com/inward/record.url?scp=55549145071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55549145071&partnerID=8YFLogxK

U2 - 10.1038/nm.1882

DO - 10.1038/nm.1882

M3 - Article

VL - 14

SP - 1264

EP - 1270

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 11

ER -